Most people know which foods to avoid for a healthy heart. Yet, do you often think about the foods you eat and how they ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

Did you know weak leg muscles accelerate cognitive decline & dementia risk after 40? Learn how to strengthen legs for better ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Semaglutide, the drug behind weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline among people with ...

Circular Genomics, Inc., the world-leading developer of circular RNA-based precision medicine tools for neurology and ...

Investing.com -- INmune Bio Inc (NASDAQ:INMB) stock dropped 4.6% Monday following the release of new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s ...

Investing.com -- ProMIS Neurosciences Inc (NASDAQ:PMN) stock climbed 6% on Monday following the publication of research supporting the company’s biomarker-driven approach to Alzheimer’s disease ...

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive degradation of brain cells, as well ...

The test confirms the scientific validity of the biomarkers used in the lab, led by researcher Carleara Weiss, and increases ...

Americans are more likely to visit their eye doctor than their primary care provider. And that’s one big reason why a company out of California is working with Banner Alzheimer’s Institute in Arizona ...

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its ...